Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects
Early diagnosis and treatment of rheumatoid arthritis (RA) are of critical importance to halt the progression of the disease. Optimal use of advanced imaging techniques or biomarkers may facilitate early diagnosis of RA. Even though many disease-modifying anti-rheumatic drugs (DMARDs) are available...
Saved in:
| Main Authors: | Bruno Fautrel, Josef S Smolen, Fabrizio Benedetti, Roberto Caporali, Thomas Doerner, Burkhard Pieper, Minjun Jang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-06-01
|
| Series: | RMD Open |
| Online Access: | https://rmdopen.bmj.com/content/7/2/e001637.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Era of biosimilars in rheumatology: reshaping the healthcare environment
by: Josef S Smolen, et al.
Published: (2019-05-01) -
Biosimilars, the journey has begun
by: Alba Martos-Rosa, et al.
Published: (2015-01-01) -
Placebo and nocebo effects in the motor system
by: Mirta Fiorio
Published: (2025-01-01) -
Placebo and nocebo effects in the neurological practice
by: Caroline Bittar, et al.
Published: (2015-01-01) -
The Influence of Expectation on Nondeceptive Placebo and Nocebo Effects
by: Hua Wei, et al.
Published: (2018-01-01)